All Posts Tagged With: "Johnson & Johnson"
(JNJ) Protect Yourself From Gold
Gold is supposed to act as a safe haven from crisis and a hedge against inflation. But lately, it hasn’t been either. You would think with the bombastic manchild leader in North Korea threatening nuclear Armageddon and the usual problems in the Middle East, investors would flock to gold....2May2013 | InvestmentU | Comments Off | Continued
(JNJ) BioLineRx to Start BL-8040 Study
BioLineRx (BLRX) recently received approval in the US for the initiation of a multi-center, open-label phase IIa study on BL-8040. BioLineRx is looking to develop BL-8040 for the treatment of acute myeloid leukemia (AML) and other...27Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) Will Johnson & Johnson Miss on Earnings?
Johnson & Johnson (JNJ) is scheduled to report its first quarter 2013 results on Apr 16, 2013 before the opening bell. Last quarter, the company posted a 1.71% positive surprise. Let’s see how things are shaping up prior...23Apr2013 | vitalstocks | Comments Off | Continued
(PCYC) Pharmacyclics Earns 4th Milestone
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus chlorambucil in elderly patients...21Apr2013 | vitalstocks | Comments Off | Continued
(OGXI) OncoGenex Pharmaceuticals’ OGX-427 Progresses
OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of previously untreated advanced non-squamous non-small...21Apr2013 | vitalstocks | Comments Off | Continued
(GILD) Gilead Sciences Seeks FDA Approval
Gilead Sciences (GILD) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its hepatitis C Virus (HCV) candidate sofosbuvir (formerly GS-7977). Gilead is looking...18Apr2013 | vitalstocks | Comments Off | Continued
(COV) Covidien plc Rolls Out More Concerta Drugs
Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), launched more dosages of the Concerta (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII). The company introduced the new 36 mg and 54 mg dosage strengths. In...11Apr2013 | vitalstocks | Comments Off | Continued
(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews
The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...7Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...31Jan2013 | Shawn | Comments Off | Continued
(AZN) Management Expands at AstraZeneca
AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued. We note that three of the seven newly created positions are...22Jan2013 | Shawn | Comments Off | Continued
(AAPL) Fourth Quarter 2012 Earnings Season Gets Into High Gear – Earnings Preview
The fourth quarter reporting season gets into high gear this week, with 253 companies coming out with quarterly results, including 83 S&P 500 companies. The earnings season thus far has been relatively uneventful, but we will have a better idea by the end of this week; by then we will have seen...20Jan2013 | Shawn | Comments Off | Continued
(DLR) Digital Realty Trust Expands in Australia
In order to expand its Australian footprints, Digital Realty Trust Inc. (DLR) recently acquired an established data center in Macquarie Park, New South Wales for AU$11.75 million. The inclusion of this high-quality...16Jan2013 | Shawn | Comments Off | Continued
(ALKS) Alkermes Maintains Fiscal 2013 View
Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to expect adjusted earnings per share in the range of $0.88-$1.02. The Zacks Consensus Estimate is pegged below the company’s...15Jan2013 | Shawn | Comments Off | Continued
(DEB) Shire to Buy Lotus Tissue Repair
Shire plc (SHPG) recently announced its intention to acquire privately-held biotech company, Lotus Tissue Repair, Inc. Lotus Tissue Repair is developing a protein replacement therapy for the treatment of dystrophic epidermolysis...15Jan2013 | Shawn | Comments Off | Continued
(COV) Covidien Drug Wins U.S. Food and Drug Administration Approval
Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), has won the U.S. Food and Drug Administration (FDA) approval to manufacture and sell a generic version of CONCERTA (methylphenidate HCl) Extended-Release (ER) Tablets...3Jan2013 | Shawn | Comments Off | Continued
(MDVN) Medivation Analyst Neutral on Shares
We recently reiterated a Neutral recommendation on Medivation, Inc. (MDVN). Medivation received a major boost in late August when the FDA approved its prostate cancer treatment, Xtandi, several months ahead of the target date. Xtandi,...2Jan2013 | Shawn | Comments Off | Continued
(COV) Covidien Remains at Neutral
We have reiterated our Neutral recommendation on leading health care products maker, Covidien plc. (COV), with a target price of $60. The company’s adjusted earnings per share (from continuing operations) of $1.02 for the...1Jan2013 | Shawn | Comments Off | Continued
(JNJ) Back to Neutral on Bayer
We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price. Bayer performed impressively...31Dec2012 | Shawn | Comments Off | Continued
(COV) Covidien plc Presents Positive Study Results
Covidien plc. (COV), a large-cap healthcare products company, has announced the five-year results of the ClosureFAST Long-Term European Multi-Center Study. The study revealed that the ...28Dec2012 | Shawn | Comments Off | Continued
(BSX) Boston Scientific Corporation Initiates Ingevity Trial
Boston Scientific Corporation (BSX) recently commenced a trial for its next-generation Ingevity pacing leads. The first patient was implanted to evaluate the safety, effectiveness and ...27Dec2012 | Shawn | Comments Off | Continued
(MYGN) Myriad Genetics Shares Upgraded to Outperform
Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), provider of molecular diagnostic products, to Outperform with a target price of $33. Myriad started...24Dec2012 | Shawn | Comments Off | Continued
(GSK) GlaxoSmithKline Anthrax Drug Gets FDA Nod
GlaxoSmithKline (GSK) recently announced that its inhalation anthrax candidate, raxibacumab, has received US Food and Drug Administration (FDA) approval. Raxibacumab was approved for inhalational anthrax caused by bacillus anthracis...23Dec2012 | Shawn | Comments Off | Continued
(MRK) Merck Ties Up with GE Healthcare
Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s Alzheimer’s disease candidate, MK-8931. Merck...23Dec2012 | Shawn | Comments Off | Continued
(JNJ) Actelion Announces Positive Data on Drug Candidate
Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is evaluating ponesimod as a treatment for patients suffering from moderate-to-severe chronic plaque psoriasis. The...21Dec2012 | Shawn | Comments Off | Continued
(CHMP) Isis Pharmaceuticals’ Kynamro Earns Negative Report From European Medicines Agency
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Isis Pharmaceuticals Inc. (ISIS) and partner Genzyme’s, a Sanofi (SNY)...19Dec2012 | Shawn | Comments Off | Continued
(AZN) AstraZeneca’s RA Drug Disappoints
AstraZeneca (AZN) and its partner Rigel Pharmaceuticals (RIGL) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib...14Dec2012 | Shawn | Comments Off | Continued
(MRK) Merck’s Alzheimer’s Drug Progresses
Merck (MRK) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral ?-amyloid precursor protein site-cleaving enzyme (BACE)...11Dec2012 | Shawn | Comments Off | Continued
(MRK) Pharmaceuticals and Biotech Stock Outlook – December 2012 – Industry Outlook
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...7Dec2012 | vitalstocks | Comments Off | Continued
(SMA) Symmetry Medical’s Surgical Subsidiary Gains Ground in Italy
Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical Inc. (SMA) recently inked an exclusive agreement in Italy with Biocommerciale Srl. Per the agreement, Biocomerciale...4Dec2012 | vitalstocks | Comments Off | Continued
(GILD) Gilead Sciences Reports Positive HCV Data
Gilead Sciences (GILD) recently presented encouraging top-line data from a phase III study (Positron) which evaluated its candidate sofosbuvir (formerly GS-7977) combined with ribavirin in patients suffering...4Dec2012 | vitalstocks | Comments Off | Continued